Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling.
暂无分享,去创建一个
Sarah Wordsworth | Deborah A. Marshall | Maarten Joost IJzerman | Kathryn A. Phillips | Luiza R. Grazziotin | Dean A. Regier | James Buchanan | M. IJzerman | D. Marshall | D. Regier | K. Phillips | S. Wordsworth | J. Buchanan | L. Grazziotin
[1] J P Kassirer,et al. The journal's policy on cost-effectiveness analyses. , 1994, The New England journal of medicine.
[2] S. Scholz,et al. Modeling rheumatoid arthritis using different techniques - a review of model construction and results , 2014, Health Economics Review.
[3] Nathaniel D Osgood,et al. Selecting a dynamic simulation modeling method for health care delivery research-part 2: report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[4] Jonathan Karnon,et al. Model Parameter Estimation and Uncertainty: a Report of the Ispor-smdm Modeling Good Research Practices Task Force-6 Background to the Task Forcemodel-parameter-estimation-and- Uncertainty-analysis.asp). a Summary of These Articles Was Pre- Sented at a Plenary Session at the Ispor 16th Annual Intern , 2022 .
[5] Koen Degeling,et al. Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models , 2017, BMC Medical Research Methodology.
[6] Jagpreet Chhatwal,et al. Economic Evaluations with Agent-Based Modelling: An Introduction , 2015, PharmacoEconomics.
[7] M. Atkins,et al. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. , 2018, Immunotherapy.
[8] R. Eldessouki,et al. Health Care System Information Sharing: A Step Toward Better Health Globally. , 2012, Value in health regional issues.
[9] D. Owens,et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[10] Maarten J. IJzerman,et al. Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. , 2018, Cancer epidemiology.
[11] M. Drummond,et al. Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .
[12] Hendrik Koffijberg,et al. A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models , 2017, Expert review of pharmacoeconomics & outcomes research.
[13] A. Briggs,et al. Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine? , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[14] Beate Jahn,et al. Resource Modelling: The Missing Piece of the HTA Jigsaw? , 2014, PharmacoEconomics.
[15] G. Baynam,et al. Optimizing Precision Medicine for Public Health , 2019, Front. Public Health.
[16] Eric Bonabeau,et al. Agent-based modeling: Methods and techniques for simulating human systems , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[17] Manish K. Mishra,et al. Integrating systems engineering practice with health-care delivery , 2014 .
[18] C. Mitton,et al. Breaking the addiction to technology adoption. , 2014, Health economics.
[19] U. Siebert,et al. Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria , 2015, SpringerPlus.
[20] Stirling Bryan,et al. Transparency in Decision Modelling: What, Why, Who and How? , 2019, PharmacoEconomics.
[21] Rom Langerak,et al. Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[22] Jörgen Möller,et al. Discrete event simulation: the preferred technique for health economic evaluations? , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[23] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[24] D. Marshall,et al. Do economic evaluations of targeted therapy provide support for decision makers? , 2011, The American journal of managed care.
[25] Maarten J. IJzerman,et al. Constrained Optimization Methods in Health Services Research-An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[26] Brian T. Denton,et al. Improving Patient Access to Chemotherapy Treatment at Duke Cancer Institute , 2013, Interfaces.
[27] Itai Ashlagi,et al. Kidney Exchange and the Alliance for Paired Donation: Operations Research Changes the Way Kidneys Are Transplanted , 2015, Interfaces.
[28] Jörgen Möller,et al. Advantages and disadvantages of discrete-event simulation for health economic analyses , 2016, Expert review of pharmacoeconomics & outcomes research.
[29] Xiange Zhang,et al. Application of discrete event simulation in health care: a systematic review , 2018, BMC Health Services Research.
[30] Deirdre Weymann,et al. Valuation of Health and Nonhealth Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[31] M J Buxton,et al. Modelling in economic evaluation: an unavoidable fact of life. , 1997, Health economics.
[32] Milton C. Weinstein,et al. Recent Developments in Decision-Analytic Modelling for Economic Evaluation , 2012, PharmacoEconomics.
[33] Kathryn A Phillips,et al. Themed Section: Assesing the Value of Next-Generation Sequencing Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions , 2018 .
[34] Kathryn A Phillips,et al. Precision Medicine: From Science To Value. , 2018, Health affairs.
[35] David C. Lane,et al. Invited Review and Reappraisal Industrial Dynamics. , 1997 .
[36] Maarten J. IJzerman,et al. Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material , 2019, Breast Cancer Research and Treatment.
[37] Uwe Siebert,et al. Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online , 2017, BMC Cancer.
[38] Maarten J. IJzerman,et al. Applying dynamic simulation modeling methods in health care delivery research-the SIMULATE checklist: report of the ISPOR simulation modeling emerging good practices task force. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[39] A. Levy,et al. HEALTH TECHNOLOGY ASSESSMENT AND PERSONALIZED MEDICINE: ARE ECONOMIC EVALUATION GUIDELINES SUFFICIENT TO SUPPORT DECISION MAKING? , 2014, International Journal of Technology Assessment in Health Care.
[40] J. Blay,et al. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] Jonathan Karnon,et al. Modeling Using Discrete Event Simulation , 2012 .
[42] M. Hoogendoorn,et al. Broadening the Perspective of Cost-Effectiveness Modeling in Chronic Obstructive Pulmonary Disease: A New Patient-Level Simulation Model Suitable to Evaluate Stratified Medicine. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[43] T. Schelling. Models of Segregation , 1969 .